GENENTECH, INC for GENENTECH INC

Taxation/Internal Revenue Code TAX

- Issues related to the tax reform bill and implementation - Issues related to supply chain incentives

Contacted: Health & Human Services, Dept of (HHS); Executive Office of the President (EOP); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); White House Office; SENATE; Office of Management & Budget (OMB)

Financial Institutions/Investments/Securities FIN

- Foreign Investment Risk Review Modernization Act (FIRRMA) H.R. 5841/S. 2098 legislation that would reform the Committee on Foreign Investment in the United States (CFIUS)

Contacted: Centers For Medicare and Medicaid Services (CMS); White House Office; Health & Human Services, Dept of (HHS); Executive Office of the President (EOP); HOUSE OF REPRESENTATIVES; Office of Management & Budget (OMB); SENATE

Bills named: H.R. 5841 (116th), S. 2098 (116th)

Medicare/Medicaid MMM

H.R.3 - Lower Drug Costs Now Act of 2019 S.977 - Transparent Drug Pricing Act of 2019 S.551, REFUND Act of 2019 H.R. 1520, the Purple Book Continuity Act H.R. 1503, the Orange Book Transparency Act; H.R. 1499, the Protecting Consumer Access to Generic Drugs Act H.R. 965, the CREATES Act H.R.269/S.1379, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 (P.L.116-22). S.1895, Lower Health Care Costs Act of 2019. S. 2543, Prescription Drug Pricing Reduction Act of 2019. H.R.19, Lower Costs, More Cures Act of 2019. S. 3013, Encouraging Innovative Benefit Design to Lowes Costs for Seniors Act S. 3129, Lower Cost, More Cures Act of 2019 H.R. 2296 - More Efficient Tools to Realize Information for Consumers Act H.R. 5741- Strengthening Innovation in Medicare and Medicaid Act - Issues related to Medicare and Medicaid coverage and reimbursement - Issues related to the 340B Drug Discount Program - Issues related to drug pricing - Medicare reimbursement for biosimilars - MACRA treatment and reimbursement of Part B drugs - Medicare payments for inpatient antimicrobials - Issues related to drug importation - Issues related to the International Pricing Index for Medicare Part B - Issues related to CMMI

Contacted: Centers For Medicare and Medicaid Services (CMS); Executive Office of the President (EOP); Office of Management & Budget (OMB); SENATE; HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); White House Office

Bills named: H.R. 2296 (116th), S. 1379 (116th), H.R. 3 (116th), H.R. 965 (116th), H.R. 5741 (116th), H.R. 1503 (116th), H.R. 1499 (116th), S. 551 (116th), S. 977 (116th), H.R. 19 (116th), S. 2543 (116th), H.R. 269 (116th), S. 3129 (116th), S. 1895 (116th), H.R. 1520 (116th), S. 3013 (116th)

Trade (domestic/foreign) TRD

H.R.2209 - Fixing Global Freeloading Act - Issues relating to trade policy and negotiations impacting the biopharmaceutical industry - Issues related to the United States-Mexico-Canada Agreement

Contacted: Executive Office of the President (EOP); White House Office; Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); SENATE; Office of Management & Budget (OMB)

Bills named: H.R. 2209 (116th)

Pharmacy PHA

S.2543: Prescription Drug Pricing Reduction Act of 2019. H.R.3: Lower Drug Costs Now Act of 2019. H.R.19: Lower Costs, More Cures Act of 2019. S.551, REFUND Act of 2019 - Drug pricing issues - Prescription Drug User Fee Act reauthorization - HR 4710, 340B Pause Act and other issues relating to the 340B Drug Discount Program - Issues related to prescription drug value

Contacted: SENATE; Office of Management & Budget (OMB); Executive Office of the President (EOP); Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; White House Office

Bills named: H.R. 3 (116th), H.R. 4710 (116th), S. 2543 (116th), S. 551 (116th), H.R. 19 (116th)

Foreign Relations FOR

- Issues related to Foreign Agents Registration Act (FARA including Disclosing Foreign Influence Act -H.R. 4170/S. 2039

Contacted: Health & Human Services, Dept of (HHS); Office of Management & Budget (OMB); Centers For Medicare and Medicaid Services (CMS); SENATE; White House Office; Executive Office of the President (EOP); HOUSE OF REPRESENTATIVES

Bills named: H.R. 4170 (116th), S. 2039 (116th)

Copyright/Patent/Trademark CPT

S.659 - Biologic Patent Transparency Act S. 1227, Prescription Pricing for the People Act of 2019 S. 1224, Stop STALLING Act S.1416 - Affordable Prescriptions for Patients Act of 2019 - Issues related to Intellectual property and process patent - Patent litigation reform - IPR process - Section 101 Reform - Compulsory licensing issues

Contacted: Executive Office of the President (EOP); Health & Human Services, Dept of (HHS); SENATE; White House Office; Office of Management & Budget (OMB); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES

Bills named: S. 1227 (116th), S. 1224 (116th), S. 659 (116th), S. 1416 (116th)

Health Issues HCR

S. 3548 - CARES Act (Coronavirus Stimulus 3) H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act H.R.6294 - Re-Valuing Anti-Microbial Products (REVAMP) Act of 2018 S.340- CREATES Act of 2019 H.R. 2113 - The Prescription Drug STAR Act H.R. 1520, the Purple Book H.R. 1499, the Protecting Cok Continuity Act; H.R. 1503, the Orange Book Transparency Act;consumer Access to Generic Drugs Act; and H.R. 965, the CREATES Act; H.R.3: Lower Drug Costs Now Act of 2019 S.1895, Lower Health Care Costs Act of 2019 S.551, REFUND Act of 2019 - Issues related to the 340B Drug Discount Program - Issues relating to drug pricing - Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. - Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. - General education about policies impacting pharmaceutical development, approval, reimbursement and pricing. -Issues related to healthcare legislation - Patient access to Part B medicines during the COVID-19 public health emergency

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Office of Management & Budget (OMB); White House Office; Executive Office of the President (EOP); Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS)

Bills named: H.R. 1503 (116th), H.R. 2113 (116th), S. 551 (116th), H.R. 1499 (116th), H.R. 6201 (116th), H.R. 6074 (116th), S. 1895 (116th), H.R. 965 (116th), H.R. 3 (116th), S. 3548 (116th), S. 340 (116th), H.R. 1520 (116th), H.R. 6294 (116th)

Budget/Appropriations BUD

H.R.5961/S.2976, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2019; H.R.6157, Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (P.L.115-245) S. 3158, Department of Labor, Health & Human Services, and Education, and Related Agencies Appropriations Act of 2019; H.J.Res.31, Consolidated Appropriations Act, 2019 (P.L.116-6); FY 2020 H.R.3164, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2020 and H.R.3055, the FY2020 Consolidated measure. H.R.2740, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2020 and the FY2020 Consolidated measure. Reimbursement and vial size issues. H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act S. 3548 - CARES Act (Coronavirus Stimulus 3) - Issues related to FDA and HHS program funding for the FY20 Labor, HHS, Education and Related Agencies, and FY20 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation bills - Strategic National Stockpile (SNS) Funding and Oversight - Patient access to Part B medicines during the COVID-19 public health emergency

Contacted: Office of Management & Budget (OMB); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); SENATE; Executive Office of the President (EOP); Health & Human Services, Dept of (HHS); White House Office

Bills named: H.R. 3164 (116th), H.R. 6201 (116th), S. 2976 (116th), H.R. 5961 (116th), S. 3158 (116th), H.R. 3055 (116th), S. 3548 (116th), H.J.Res. 31 (116th), H.R. 6074 (116th), H.R. 2740 (116th), H.R. 6157 (116th)

Medical/Disease Research/Clinical Labs MED

S. 2852 Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 S. 3548 - CARES Act (Coronavirus Stimulus 3) H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act - Issues related to public health protection including influenza development and preparedness - Issues related to antimicrobial and antiviral research and product development - Issues related to novel coronavirus and COVID-19 research and product development

Contacted: SENATE; Executive Office of the President (EOP); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); White House Office; Office of Management & Budget (OMB); Centers For Medicare and Medicaid Services (CMS)

Bills named: H.R. 6074 (116th), H.R. 6201 (116th), S. 2852 (116th), S. 3548 (116th)